Last $105.25 USD
Change Today +2.09 / 2.03%
Volume 384.6K
PCRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

pacira pharmaceuticals inc (PCRX) Snapshot

Open
$103.77
Previous Close
$103.16
Day High
$107.69
Day Low
$102.23
52 Week High
08/29/14 - $109.94
52 Week Low
09/19/13 - $40.53
Market Cap
3.8B
Average Volume 10 Days
344.8K
EPS TTM
$-1.28
Shares Outstanding
35.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PACIRA PHARMACEUTICALS INC (PCRX)

pacira pharmaceuticals inc (PCRX) Related Bloomberg News

View More Bloomberg News

pacira pharmaceuticals inc (PCRX) Related Businessweek News

No Related Businessweek News Found

pacira pharmaceuticals inc (PCRX) Details

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company commercializes EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase III clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate, an oncology preclinical candidate, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

308 Employees
Last Reported Date: 02/25/14
Founded in 2006

pacira pharmaceuticals inc (PCRX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $916.2K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $468.4K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $458.9K
Chief Medical Officer
Total Annual Compensation: $367.6K
Principal Accounting Officer and Executive Di...
Total Annual Compensation: $288.4K
Compensation as of Fiscal Year 2013.

pacira pharmaceuticals inc (PCRX) Key Developments

Pacira Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Pacira Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $47,165,000 compared with $17,141,000 for the quarter ended June 30, 2013. The company reported loss from operations of $2,842,000 and loss before income taxes of $5,037,000 against loss from operations of $12,010,000 and loss before income taxes of $14,031,000 a year ago. Net loss was $5,037,000, or $0.14 per basic and diluted share compared to $14,031,000 or $0.42 per basic and diluted share for the quarter ended June 30, 2013. Non-GAAP net income was $1,535,000 or $0.04 per basic and diluted share compared to loss of $10,771,000 or $0.33 per basic and diluted share a year ago. Capex in the quarter was $6 million. For the six months, the company reported total revenues of $83,828,000 compared with $28,728,000 for the quarter ended June 30, 2013. The company reported loss from operations of $12,099,000 and loss before income taxes of $16,514,000 against loss from operations of $30,656,000 and loss before income taxes of $37,611,000 a year ago. Net loss was $16,514,000, or $0.48 per basic and diluted share compared to $37,169,000 or $1.13 per basic and diluted share for the quarter ended June 30, 2013. Non-GAAP net loss was $4,933,000 or $0.14 per basic and diluted share compared to $27,431,000 or $0.83 per basic and diluted share a year ago.

Pacira Pharmaceuticals, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 08:35 AM

Pacira Pharmaceuticals, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 08:35 AM. Venue: Le Parker Meridien, New York, New York, United States. Speakers: David M. Stack, Chairman, Chief Executive Officer and President.

Pacira Pharmaceuticals, Inc. to Report Q2, 2014 Results on Jul 31, 2014

Pacira Pharmaceuticals, Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCRX:US $105.25 USD +2.09

PCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $46.10 USD +0.92
Cumberland Pharmaceuticals Inc $5.03 USD +0.13
Durect Corp $1.51 USD -0.03
Stryker Corp $84.07 USD +0.13
Teleflex Inc $109.31 USD +0.32
View Industry Companies
 

Industry Analysis

PCRX

Industry Average

Valuation PCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.0x
Price/Book 25.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIRA PHARMACEUTICALS INC, please visit www.pacira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.